[IL-2 gene therapy in ENT carcinomas].
[IL-2 gene therapy in ENT carcinomas].
复制标题
[耳鼻喉癌中的IL-2基因治疗]。
作者：
S. Lang;R. Zeidler;C. Pauli;M. Andratschke;B. Wollenberg
细胞免疫抑制在头颈鳞状细胞癌 (HNSCC) 患者中很常见。先前的研究表明，施用白细胞介素 2 (IL-2) 可增强体外和体内的抗肿瘤免疫力。由于IL-2的血清半衰期相对较短，因此需要重复应用才能达到治疗有效的血清浓度，但这种策略可能会导致严重的副作用。因此，需要在较长时间内提供高局部细胞因子水平而不需要重复注射的方法。基因治疗作为一种创新的治疗方法，使用稳定转导的肿瘤细胞产生 IL-2，可能符合这些标准。体外操作的肿瘤细胞，如果在未操作的肿瘤细胞附近重新施用，可能会增强体内的特异性抗肿瘤反应，而不会产生全身副作用。本手稿回顾了当前有关 IL-2 蛋白和基因治疗的文献，特别强调头颈癌。我们自己的 IL-2 基因治疗体外结果与其他作者发表的数据相结合，支持我们部门目前正在进行的这种治疗策略的体内方法。
Suppressed cellular immunity is common in patients with squamous cell carcinoma of the head and neck (HNSCC). It was demonstrated in previous studies that administration of interleukin 2 (IL-2) results in enhanced antitumoral immunity in vitro as well as in vivo. Since the serum half-life of IL-2 is relatively short, repeated applications are necessary to achieve therapeutically effective serum concentrations, but this strategy might cause severe side effects. Therefore, methods that provide high local cytokine levels over a prolonged period of time without the need for repeated injections are desirable. Gene therapy as an innovative treatment approach using tumor cells stably transduced to produce IL-2 might meet these criteria. In vitro manipulated tumor cells, if readministered in the vicinity of non-manipulated tumor cells, may enhance a specific anti-tumor response in vivo without systemic side effects. The present manuscript reviews the current literature dealing with IL-2-protein and -gene therapy with special emphasis on head and neck cancer. Our own in vitro results with IL-2 gene therapy in conjunction with published data from other authors argue in favour of an in vivo approach for this therapeutic strategy that is currently in progress in our department.